Cargando…

Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia

Chimeric antigen receptor (CAR)-T cell therapies have shown tremendous results against various hematologic cancers. Prior to cell infusion, a host preconditioning regimen is required to achieve lymphodepletion and improve CAR-T cell pharmacokinetic exposure, leading to greater chances of therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Derippe, Thibaud, Fouliard, Sylvain, Marchiq, Ibtissam, Dupouy, Sandra, Almena-Carrasco, Maria, Geronimi, Julia, Declèves, Xavier, Chenel, Marylore, Mager, Donald E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036133/ https://www.ncbi.nlm.nih.gov/pubmed/36970053 http://dx.doi.org/10.1158/2767-9764.CRC-22-0176

Ejemplares similares

Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
por: Dupouy, Sandra, et al.
Publicado: (2022)

Influence of the Duration of Intravenous Drug Administration on Tumor Uptake
por: Fouliard, Sylvain, et al.
Publicado: (2013)

Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach
por: Tosca, Elena M., et al.
Publicado: (2021)

How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
por: Meyer, Claudia, et al.
Publicado: (2022)

P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
por: Boissel, Nicolas, et al.
Publicado: (2023)

P1420: PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES
por: Aranda Orgilles, B., et al.
Publicado: (2022)

Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H(+) symporters
por: Marchiq, Ibtissam, et al.
Publicado: (2015)

Development of a Physiologically-Based Pharmacokinetic Model of the Rat Central Nervous System
por: Badhan, Raj K. Singh, et al.
Publicado: (2014)

P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
por: Jain, N., et al.
Publicado: (2022)

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
por: Graham, Charlotte Elizabeth, et al.
Publicado: (2021)

Recent Advances in Allogeneic CAR-T Cells
por: Kim, Dong Wook, et al.
Publicado: (2020)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Knock out of the BASIGIN/CD147 chaperone of lactate/H+ symporters disproves its pro-tumour action via extracellular matrix metalloproteases (MMPs) induction
por: Marchiq, Ibtissam, et al.
Publicado: (2015)

Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report
por: Wang, Dongmei, et al.
Publicado: (2018)

Mechanistic interplay between ceramide and insulin resistance
por: Reali, Federico, et al.
Publicado: (2017)

Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report
por: Cao, Yigeng, et al.
Publicado: (2023)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status
por: Granja, Sara, et al.
Publicado: (2014)

Metabolic Plasiticy in Cancers—Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs
por: Ždralević, Maša, et al.
Publicado: (2017)

P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)
por: Ghobadi, Armin, et al.
Publicado: (2023)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Saleh, Khalil, et al.
Publicado: (2023)

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia
por: Zhao, Yan-Li, et al.
Publicado: (2021)

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
por: Valton, Julien, et al.
Publicado: (2015)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
por: Wu, Xiaolong, et al.
Publicado: (2022)

Umbilical cord blood: A promising source for allogeneic CAR-T cells
por: Liu, Dian-Dian, et al.
Publicado: (2022)

Optimized Protocol for the In Situ Derivatization of Glutathione with N-Ethylmaleimide in Cultured Cells and the Simultaneous Determination of Glutathione/Glutathione Disulfide Ratio by HPLC-UV-QTOF-MS
por: Sun, Xueni, et al.
Publicado: (2020)

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use
por: Nayak, Satyaprakash, et al.
Publicado: (2018)

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
por: Almaeen, Abdulrahman H., et al.
Publicado: (2023)

Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
por: Sugita, Mayumi, et al.
Publicado: (2023)

Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
por: Greil, C., et al.
Publicado: (2020)

Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph(+) B cell acute lymphoblastic leukemia
por: Han, Lu, et al.
Publicado: (2022)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_njsp9215hdnq5rd6023kqsdhb2